enGene Therapeutics Inc. ENGN
NASDAQ
| 07/31/2026 | 04/30/2026 | 01/31/2026 | 10/31/2025 | 07/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -37.63% | -58.80% | -77.33% | -112.73% | 22.58% |
| Total Depreciation and Amortization | 70.55% | 79.62% | 72.75% | 57.59% | 45.67% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 160.53% | 87.91% | 38.07% | 21.28% | -91.17% |
| Change in Net Operating Assets | 231.24% | 273.22% | 302.00% | 10,152.63% | -173.33% |
| Cash from Operations | -10.08% | -45.90% | -53.81% | -105.54% | -164.43% |
| Capital Expenditure | 46.50% | -138.36% | -86.49% | -60.54% | -55.88% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 83.47% | 69.02% | 68.94% | 81.08% | -- |
| Cash from Investing | 83.22% | 68.39% | 68.41% | 80.04% | -23,039.88% |
| Total Debt Issued | -- | -- | -- | -- | -100.00% |
| Total Debt Repaid | -3,198.00% | -- | -- | 92.60% | 94.93% |
| Issuance of Common Stock | 151.35% | 151.28% | -42.91% | -99.17% | -77.04% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | 19.68% | -- | 100.00% |
| Cash from Financing | 140.81% | 136.81% | -43.57% | -99.43% | -76.72% |
| Foreign Exchange rate Adjustments | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 103.73% | 86.63% | -10.44% | -234.29% | -202.26% |